By Sherri Oslick --
About Court Report: Each week we will report briefly on recently filed biotech and pharma cases.
Abbott Products Inc. et al. v. Teva Pharamceuticals USA, Inc.
1:11-cv-00384; filed April 29, 2011 in the District Court of Delaware
• Plainitffs: Abbott Products Inc.; Unimed Pharmaceuticals LLC; Besins Healthcare Inc.
• Defendant: Teva Pharmaceuticals USA, Inc.
Infringement of U.S. Patent No. 6,503,894 ("Pharmaceutical Composition and Method for Treating Hypogonadism," issued January 7, 2003) following a Paragraph IV certification as part of Teva's filing of an NDA (under § 505(b)(2) of the Food, Drug and Cosmetic Act) to manufacture a generic version of Abbott's AndroGel® (testosterone gel, used to treat conditions associated with a deficiency or absence of endogenous testosterone). View the complaint here.
AstraZeneca Pharmaceuticals LP et al. v. Osmotica Pharmaceutical Corp.
3:11-cv-02484; filed April 29, 2011 in the District Court of New Jersey
• Plaintiffs: AstraZeneca Pharmaceuticals LP; AstraZeneca UK Ltd.
• Defendant: Osmotica Pharmaceutical Corp.
AstraZeneca Pharmaceuticals LP et al. v. Mylan Pharmaceuticals Inc. et al.
3:11-cv-02483; filed April 29, 2011 in the District Court of New Jersey
• Plaintiffs: AstraZeneca Pharmaceuticals LP; AstraZeneca UK Ltd.
• Defendants: Mylan Pharmaceuticals Inc.; Mylan Inc.
The complaints in these cases are substantially identical. Infringement of U.S. Patent Nos. 4,879,288 ("Novel Dibenzothiazepine Antipsychotic," issued November 7, 1989) and 5,948,437 ("Pharmaceutical Compositions Using Thiazepine," issued September 7, 1999) following a Paragraph IV certification as part of Osmotica's filing of an ANDA to manufacture a generic version of AstraZeneca's Seroquel® XR (quetiapine fumarate, used to treat schizophrenia and bipolar disorder). View the Osmotica complaint here.
Medicines Company v. Dr. Reddy's Laboratories Ltd. et al.
3:11-cv-02456; filed April 28, 2011 in the District Court of New Jersey
• Plaintiff: Medicines Company
• Defendants: Dr. Reddy's Laboratories Ltd.; Dr. Reddy's Laboratories, Inc.; Gland Pharma, Inc.
Infringement of U.S. Patent Nos. 7,582,727 ("Pharmaceutical Formulations of Bivalirudin and Process of Making the Same," issued September 1, 2009) and 7,598,343 (same title, issued October 6, 2009) following a Paragraph IV certification as part of Dr. Reddy's filing of an ANDA to manufacture a generic version of The Medicines Company's Angiomax® (bivalirudin, used as an anticoagulant in patients with unstable angina undergoing percutaneous translurninal coronary angioplasty). View the complaint here.
Taro Pharmaceuticals North America, Inc. et al. v. Suven Life Sciences, Ltd. et al.
3:11-cv-02452; filed April 28, 2011 in the District Court of New Jersey
• Plaintiffs: Taro Pharmaceuticals North America, Inc.; Taro Pharmaceuticals U.S.A., Inc.
• Defendants: Suven Life Sciences, Ltd.; Suven Life Sciences USA, LLC
Infringement of U.S. Patent No. 7,560,445 ("Process for Preparing Malathion for Pharmaceutical Use," issued July 14, 2009) following a Paragraph IV certification as part of Suven's filing of an ANDA to manufacture a generic version of Taro's Ovide® (malathion lotion, used to treat head lice). View the complaint here.
Shire LLC et al. v. Sandoz Inc.
1:11-cv-01110; filed April 27, 2011 in the District Court of Colorado
• Plaintiffs: Shire LLC; Supernus Pharmaceuticals, Inc.; Amy F.T. Arnsten Ph.D.; Pasko Rakic M.D.; Robert D. Hunt
• Defendant: Sandoz Inc.
Infringement of U.S. Patent Nos. 5,854,290 ("Use of Guanfacine in the Treatment of Behavioral Disorders," issued December 19, 1998), 6,287,599 ("Sustained Release Pharmaceutical Dosage Forms with Minimized pH Dependent Dissolution Profiles," issued September 11, 2001), and 6,811,794 (same title, issued November 2, 2004) based on Sandoz's filing of an ANDA to manufacture a generic version of Shire's Intuniv® (guanfacine, used to treat attention-deficit hyperactivity disorder). View the complaint here.
Genzyme Corp. v. Endo Pharmaceuticals Inc.
1:11-cv-01103; filed April 27, 2011 in the District Court of Maryland
Infringement of U.S. Patent No. 5,667,775 ("Phosphate-Binding Polymers for Oral Administration," issued on September 16, 1997) following a Paragraph IV certification as part of Endo's filing of an ANDA to manufacture a generic version of Genzyme's Renvela® (sevelamer carbonate, used for the control of serum phosphorus in patients with chronic kidney disease on dialysis). View the complaint here.
Comments